0 0
    • Mark all read All chats All chats
    Finabase
    • Categories
    • Register
    • Login
    Home Watchlists Portfolios Map Forex Futures Crypto Comparisons Alerts Screeners Backtests vTrading Settings Forum
    1. Home
    2. BCRX
    • Alert
    • Note
    BCRX
    BioCryst Pharmaceuticals, Inc.
    7.35
    +
    0.19
    2.65%
    29 x 7.27
    13 x 7.37
    bid
    ask
    21 @ 04:00 PM
    7.31-0.04 (0.54%)
    Bearish 31
    Bullish 79
    sentiment
    7.07
    day range
    7.37
    6.71
    52 week range
    14.20
    04:00 PM
    V: 1.95M
    C: 7.35
    L: 7.07
    H: 7.37
    O: 7.21
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close7.16
    Open7.21
    Low7.07
    High7.37
    Volume1.95M
    Avg. Volume2.52M
    Market Cap1.39B
    Inst. Own87.08%
    Beta2.01
    Short Ratio12.29
    Div & Yield0.00 /
    EPS-1.30
    P/E0.00
    1yr Target15.15
    50day MA8.26
    200day MA11.26
    ^DJI
    Dow Jones Industrial Average
    33963.80
    05:35 PM
    -
    106.60
    0.31%
    ^IXIC
    NASDAQ Composite
    13211.80
    05:15 PM
    -
    12.20
    0.09%
    ^GSPC
    S&P 500
    4320.06
    05:35 PM
    -
    9.94
    0.23%
    AAPL
    174.95
    +0.16 (0.09%)
    Apple Inc.
    174.79
    9 @ 04:00 PM
    9 x 174.93
    9 x 175.10
    +
    0.86
    0.49%
    GOOG
    131.44
    +0.19 (0.15%)
    Alphabet Inc.
    131.25
    9 @ 04:00 PM
    8 x 131.50
    9 x 131.63
    -
    0.11
    0.08%
    AMZN
    129.30
    +0.18 (0.14%)
    Amazon.com, Inc.
    129.12
    9 @ 04:00 PM
    8 x 129.27
    10 x 129.28
    -
    0.21
    0.16%
    MSFT
    316.81
    -0.20 (0.06%)
    Microsoft Corporation
    317.01
    11 @ 04:00 PM
    8 x 316.81
    13 x 317.01
    -
    2.52
    0.79%
    BABA
    88.50
    +0.20 (0.23%)
    Alibaba Group Holding Limited
    88.30
    8 @ 04:01 PM
    8 x 88.50
    8 x 88.58
    +
    4.19
    4.98%
    NFLX
    379.65
    -0.16 (0.04%)
    Netflix, Inc.
    379.81
    10 @ 04:00 PM
    9 x 379.82
    11 x 380.43
    -
    4.34
    1.13%
    TSLA
    244.16
    -0.72 (0.29%)
    Tesla, Inc.
    244.88
    11 @ 04:00 PM
    9 x 243.86
    13 x 244.16
    -
    10.82
    4.23%
    NVDA
    415.74
    -0.36 (0.09%)
    NVIDIA Corporation
    416.10
    21 @ 04:00 PM
    11 x 415.58
    31 x 415.90
    +
    5.93
    1.45%
    AMD
    96.08
    -0.12 (0.12%)
    Advanced Micro Devices, Inc.
    96.20
    13 @ 04:00 PM
    14 x 96.01
    12 x 96.13
    +
    0.09
    0.09%
    MU
    68.89
    +0.01 (0.01%)
    Micron Technology, Inc.
    68.88
    14 @ 04:00 PM
    14 x 68.85
    13 x 68.95
    +
    0.98
    1.44%
    SPY
    430.69
    +0.27 (0.06%)
    SPDR S&P 500 ETF Trust
    430.42
    31 @ 04:00 PM
    31 x 430.52
    30 x 430.80
    -
    0.97
    0.22%
    TQQQ
    35.68
    +0.05 (0.15%)
    ProShares UltraPro QQQ
    35.63
    35 @ 04:00 PM
    40 x 35.68
    29 x 35.73
    +
    0.02
    0.07%
    BRK-A
    544000.00
    -2215.00 (0.41%)
    Berkshire Hathaway Inc.
    546215.00
    10 @ 04:00 PM
    9 x 544500.00
    10 x 547042.00
    -
    4815.00
    0.87%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? zacks.com •
    BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment proactiveinvestors.com •
    BioCryst to Present at Upcoming Investor Conferences globenewswire.com •
    BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript seekingalpha.com •
    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates zacks.com •
    BioCryst to Report Second Quarter 2023 Financial Results on August 3 globenewswire.com •
    Profile ...
    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2023-11-07 2023-09 -0.25 N/A N/A N/A
    2023-08-03 2023-06 -0.25 -0.24 0.01 4.00%
    2023-05-03 2023-03 -0.3 -0.28 0.02 6.67%
    2023-02-21 2022-12 -0.19 -0.38 -0.19 -100.00%
    2022-11-01 2022-09 -0.32 -0.23 0.09 28.13%
    2022-08-04 2022-06 -0.36 -0.32 0.04 11.11%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2023-07-13 B of A Securities Upgrade Neutral Buy
    2023-05-04 RBC Capital Upgrade Sector Perform
    2023-05-04 Needham Upgrade Buy
    2023-04-20 Evercore ISI Group Upgrade Outperform
    2023-04-20 Needham Upgrade Buy
    2023-03-14 RBC Capital Upgrade Sector Perform
    Insider Holder ...
    Date Name Relation Quantity Description
    2023-06-12 ABERCROMBIE GEORGE B Director 29.61K Stock Award(Grant)
    2023-06-12 ASELAGE STEPHEN J Director 63.34K Stock Award(Grant)
    2023-06-12 GALSON STEVEN K Director 29.61K Stock Award(Grant)
    2023-06-12 HEGGIE THERESA Director 49.11K Stock Award(Grant)
    2023-06-13 HUTSON NANCY J Director 81.82K Sale
    2023-06-12 LEE KENNETH B. Director 68.86K Stock Award(Grant)
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2023-03-30 Blackrock Inc. 14.82M 108.96M 7.85%
    2023-03-30 Vanguard Group, Inc. (The) 14.83M 108.97M 7.85%
    2023-03-30 Baker Brothers Advisors, LLC 12.71M 93.42M 6.73%
    2023-03-30 State Street Corporation 11.39M 83.71M 6.03%
    2023-03-30 Avoro Capital Advisors LLC 10.42M 76.59M 5.52%
    2023-03-30 Pictet Asset Management SA 5.62M 41.30M 2.97%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2023-02-27 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 6.52M 47.92M 3.46%
    2022-12-30 Vanguard Total Stock Market Index Fund 5.65M 41.54M 3.00%
    2023-02-27 iShares Russell 2000 ETF 4.10M 30.13M 2.18%
    2023-02-27 Fidelity Select Portfolios - Biotechnology 2.69M 19.79M 1.43%
    2022-12-30 Vanguard Extended Market Index Fund 2.52M 18.51M 1.34%
    2022-12-30 Vanguard Small-Cap Index Fund 2.40M 17.65M 1.27%
    Dividend ...
    Dividend Date
    0 2014-06-11
    0 2014-06-05
    0 2014-05-20
    0 2014-05-16
    0 2014-04-02
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes
    • 1
    • 2
    • 3
    • 4
    • 5
    • 20
    • 21
    • 1 / 21
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #384

      Toilet Stock. More money will bleed out on Monday. That’s all it ever does. It is not a Covid stock. For myself, huge mistake.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #385

      Please someone explain the sudden change in volume, in layman’s terms, Tysm

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #386

      Please can someone explain the volume? I’m a newer trader. In layman’s terms. Tysm

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #387

      Meant to say write. I misspelled because I’m so upset.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #388

      Write. Sorry. I can spell. Lol.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #389

      I am not a big time investor. I’m stuck in this pos stock. I’m now convinced more then ever this Company is Shady. I had 30 shares limit buy at 3.95. I saw it drop to pick it up then right back up. I don’t know much but I’m convinced this is rigged. It’s doing it again as I right this. Dipping down sudden then back up.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 19 - last edited by
      #390

      It’s going nowhere.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 18 - last edited by
      #391

      Any year now. Maybe 2022 will be the year

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 17 - last edited by
      #392

      If Gladisvir was even possibly going to be a contender in Covid wouldn’t there be some shred of news out on that lately? I hope the positive hopes are correct but it feels like grasping at straws at this point. This stock needs to S—- or get off the pot. There’s just crickets on BCRX.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 17 - last edited by
      #393

      It just keeps getting better and better. Nightmare stock

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #394

      Shady Shady something is not right here. Controlled stock. Live and learn. First dilution then you notice the pattern.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #395

      Manipulated stock. Want out. Waste of time.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #396

      Let’s be honest this stock is broken. NG

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #397

      Same volume same price range day in and day out. Like watching paint dry

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #398 
                                        Why doesn’t this stock ever move? If I was even ,I’d get out and buy back later. It just shows no signs of life.
      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #399

      It’s just stuck! Zzzzz

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 16 - last edited by
      #400

      Re Dexamethasone is all you need, that news states it’s for severe cases and patients are already vented. The key would be meds that treat you before you get to that point.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #401

      @Vafa sorry my words connected. Can’t find edit here.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #402

      @Vafabbut when will that news hit be? The last news didn’t do anything imo.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #403

      Company still selling shares at 4.50 target? They are still raising cash? How many shares do they have left to sell?

      1 Reply Last reply
      0
    • 1
    • 2
    • 3
    • 4
    • 5
    • 20
    • 21
    • 1 / 21

    • BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
      zacks.com •

    • BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
      proactiveinvestors.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
      zacks.com •

    • BioCryst to Report Second Quarter 2023 Financial Results on August 3
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Is Soaring Today
      fool.com •

    • BioCryst to Report First Quarter 2023 Financial Results on May 3
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst: Good Candidate For Buyout, But Not For Anything Else
      seekingalpha.com •

    • Why Shares of BioCryst Pharmaceuticals Jumped Today
      fool.com •

    • BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
      seekingalpha.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
      seekingalpha.com •

    • Why BioCryst Pharmaceuticals Stock Is Sinking Today
      fool.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
      zacks.com •

    • Why Earnings Season Could Be Great for BioCryst (BCRX)
      zacks.com •

    • BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
      globenewswire.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
      globenewswire.com •

    • Pharmaceutical Stock Sinks on Sales Forecast
      schaeffersresearch.com •

    • BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
      globenewswire.com •

    • BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
      seekingalpha.com •

    • BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
      zacks.com •

    • BCRX Stock Sinks as BioCryst Discontinues Drug Development
      investorplace.com •

    • BioCryst to discontinue development of drug
      marketwatch.com •

    • BioCryst to Present at JMP Securities Hematology & Oncology Summit
      globenewswire.com •

    • 3 Biotechnology stocks under 10 dollars to buy now
      thedogofwallstreet.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
      zacks.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
      globenewswire.com •

    • CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
      investors.com •

    • BioCryst to Report Third Quarter 2022 Financial Results on November 1
      globenewswire.com •

    • Got $3,000? Here Are 2 Stocks That Will Make You Richer
      fool.com •

    • 3 Biotech Stocks to Buy Now for Extraordinary Gains
      investorplace.com •

    • Options Bulls Blast Phama Stock on Lifted Clinical Hold
      schaeffersresearch.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call Transcript
      seekingalpha.com •

    • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
      fool.com •

    • 3 Fast-Growing Stocks to Buy Now
      fool.com •

    • BioCryst to Report Second Quarter 2022 Financial Results on August 4
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • BioCryst: A Prudent Diversification
      seekingalpha.com •

    • Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
      zacks.com •

    • Why BioCryst Pharmaceuticals Topped the Market Today
      fool.com •

    • 7 Cheap Biotech Stocks to Buy Now
      investorplace.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • Why BioCryst Stock Lost Nearly 4% of Its Value Today
      fool.com •

    • Why BioCryst Stock Shot Nearly 5% Higher Today
      fool.com •

    • BioCryst to Report First Quarter 2022 Financial Results on May 5
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Sank Today
      fool.com •

    • Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
      fool.com •

    • Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
      zacks.com •

    • BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
      zacks.com •

    • Why BioCryst Pharmaceuticals Stock Is Falling
      benzinga.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
      benzinga.com •

    • Why BioCryst Pharmaceuticals Stock Is Plunging Today
      benzinga.com •

    • Why BioCryst Pharmaceuticals Stock Slid Today
      fool.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
      zacks.com •

    • Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?
      benzinga.com •

    • Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals
      seekingalpha.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
      fool.com •

    • BioCryst Pharmaceuticals Stock (BCRX): Why The Price Surged Today
      pulse2.com •

    • Why BioCryst Pharmaceuticals Stock Is Jumping on Monday
      fool.com •

    • BioCryst Provides Tremendous Option Value
      seekingalpha.com •

    • BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
      seekingalpha.com •

    • BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
      zacks.com •

    • BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
      benzinga.com •

    • 7 Top Growth Stocks to Buy as We Step Into November
      investorplace.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
      fool.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
      globenewswire.com •

    • BioCryst to Report Third Quarter 2021 Financial Results on November 3
      globenewswire.com •

    • 7 Best Growth Stocks to Buy and Hold for the Next 10 Years
      investorplace.com •

    • 2 Super-Charged Growth Stocks to Buy Now
      fool.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • 3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
      fool.com •

    • NICE Recommends BioCryst's Hereditary Angioedema Med
      benzinga.com •

    • NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
      globenewswire.com •

    • What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
      seekingalpha.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
      benzinga.com •

    • U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
      globenewswire.com •

    • BioCryst Appoints Dr. Steven Galson to Board of Directors
      globenewswire.com •

    • BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
      globenewswire.com •

    • 2 Soaring Biotech Stocks With More Fuel in the Tank
      fool.com •

    • BioCryst Stock Jumps After Pulling Out $200M Equity Raise
      benzinga.com •

    • BioCryst Withdraws Public Offering
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Rose 8% on Thursday
      fool.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharma Stock Heads Higher Thursday: Here's Why
      benzinga.com •

    • Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More
      247wallst.com •

    • 3 Biotech Stocks That Could Rocket Higher
      fool.com •

    • BioCryst to Report Second Quarter 2021 Financial Results on August 5
      globenewswire.com •

    • BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
      seekingalpha.com •

    • BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
      benzinga.com •

    • First post
      Last post
    0
    • Categories
    • Login
    • Don't have an account? Register
    • Login or register to search.
    Copyright © 2023 finabase.io